Literature DB >> 8356046

Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.

M Furlan1, R Robles, D Affolter, D Meyer, P Baillod, B Lämmle.   

Abstract

High molecular weight (HMW) and low molecular weight (LMW) forms of von Willebrand factor (vWF) were isolated from normal human plasma in the presence of protease inhibitors. HMW and LMW vWF preparations were subjected to reduction of interdimeric disulfide bridges under mild reducing conditions. Following sodium dodecyl sulfate electrophoresis in 3% agarose, the vWF bands were detected by immunoblotting with a polyclonal rabbit anti-vWF antiserum as well as with two monoclonal antibodies directed against epitopes located in the NH2-terminal (MAb 418) or in the COOH-terminal (MAb 9) region of the vWF subunit. Our results suggest that the slowest migrating band of the dimeric triplet set of LMW vWF represents an asymmetric structure composed of an intact subunit to which one NH2-terminal and one COOH-terminal fragment are linked by disulfide bridges. The intermediate band of the first triplet of LMW vWF strongly reacted with MAb 9 but not with MAb 418, indicating that it represents a dimer of COOH-terminal fragments. The fastest migrating band of the same triplet is apparently a dimer of the NH2-terminal fragments because it reacted with MAb 418 but not with MAb 9. Each next higher family of triplets seems to contain one more asymmetric fragment of dimeric size. These results are compatible with a model according to which LMW forms of vWF are derived from HMW vWF by proteolytic cleavage in the circulating blood.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8356046      PMCID: PMC47170          DOI: 10.1073/pnas.90.16.7503

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Letter: A method for assaying von Willebrand factor (ristocetin cofactor).

Authors:  D E Macfarlane; J Stibbe; E P Kirby; M B Zucker; R A Grant; J McPherson
Journal:  Thromb Diath Haemorrh       Date:  1975-09-30

2.  Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor.

Authors:  R B Counts; S L Paskell; S K Elgee
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

3.  Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

4.  Willebrand factor: immunological and biological study.

Authors:  D Meyer; M D Dreyfus; M J Larrieu
Journal:  Pathol Biol (Paris)       Date:  1973-11

5.  A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor.

Authors:  G Castaman; F Rodeghiero; A Lattuada; P M Mannucci
Journal:  Thromb Res       Date:  1992-02-01       Impact factor: 3.944

6.  Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers.

Authors:  B A Perret; M Furlan; E A Beck
Journal:  Biochim Biophys Acta       Date:  1979-05-23

7.  Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC).

Authors:  Z M Ruggeri; I M Nilsson; R Lombardi; L Holmberg; T S Zimmerman
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

8.  Epitope mapping by cDNA expression of a monoclonal antibody which inhibits the binding of von Willebrand factor to platelet glycoprotein IIb/IIIa.

Authors:  G Piétu; A S Ribba; G Chérel; D Meyer
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

9.  Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.

Authors:  L W Hoyer; J R Shainoff
Journal:  Blood       Date:  1980-06       Impact factor: 22.113

10.  The complex multimeric composition of factor VIII/von Willebrand factor.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

View more
  10 in total

Review 1.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

2.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

3.  Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome.

Authors:  Y Sasahara; S Kumaki; Y Ohashi; M Minegishi; H Kano; F Bessho; S Tsuchiya
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

4.  Triplet structure of human von Willebrand factor.

Authors:  B E Fischer; K B Thomas; U Schlokat; F Dorner
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

5.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

6.  Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.

Authors:  A Casonato; E Pontara; A Bertomoro; D Dannhauser; S Secchiero; M Zaninotto; A Girolami
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

Review 7.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

Review 8.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.

Authors:  Marcus Stockschlaeder; Reinhard Schneppenheim; Ulrich Budde
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

Review 9.  Acquired Von Willebrand Deficiency in Adults With Aortic Stenosis: A Systematic Review.

Authors:  Prasana Ramesh; Suthasenthuran Kanagalingam; Fnu Zargham Ul Haq; Nishok Victory Srinivasan; Aujala Irfan Khan; Ghadi D Mashat; Mohammad Hazique; Kokab Irfan Khan; Safeera Khan
Journal:  Cureus       Date:  2022-09-07

10.  Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease.

Authors:  Johan Boender; Ferdows Atiq; Marjon H Cnossen; Johanna G van der Bom; Karin Fijnvandraat; Joke de Meris; Moniek P M de Maat; Karin P M van Galen; Britta A P Laros-van Gorkom; Karina Meijer; Jeroen Eikenboom; Frank W G Leebeek
Journal:  Hemasphere       Date:  2021-02-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.